Dyax Corp. (DYAX) Sells 7.4M Shares at $2.02
More News related to DYAX
- DX-88 (ecallantide) Demonstrated Relief of Symptoms in Hereditary Angioedema Acute Attacks in All Attack Locations
- National Securities Initiates Coverage on Dyax (DYAX) with a Buy
- Trading Radar for 10/28: First Solar (FSLR), ConocoPhillips (COP), WellPoint (WLP), Goodyear (GT), Int. Paper (IP) Report
- Dyax Corp. (DYAX) Posts Q3 Loss of $0.17, Wider Than Expected
- Dyax Corp. Announces Third Quarter 2009 Financial Results
More News related to Equity Offerings
- Hemispherx Biopharma (HEB) Reports a Q3 Loss; Comments on FDA Responses
- Wright Medical Group (WMGI) Announces FDA Approval For CONSERVE Plus Total Hip Resurfacing System
- Vascular Solutions (VASC) Receives 501(k) Clearance from U.S. FDA for GuideLiner Catheter
- Glaxo (GSK) and XenoPort (XNPT) Announed that U.S. FDA Has Extended the Review Date of GSK1838262/XP13512
- Compugen (CGEN) Announces Discovery of Biomarker CGEN-40001 for Type 2 Diabetes
Dyax Corp. (NASDAQ: DYAX) agreed to sell 7,425,743 shares of its common stock at a price of $2.02 per share in an underwritten public offering with no warrants. The price per share is equal to the closing price of Dyax’s common stock on June 24, 2009.
Deutsche Bank Securities Inc. is the sole underwriter for the offering.
Dyax intends to use the net proceeds from the offering to fund the development and commercialization of DX-88, the Company’s ongoing research and preclinical activities, and for general corporate purposes
Related Categories
Equity OfferingsStocks Mentioned
+0.13Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
